Catalog # DXD-M684



#### Source

Monoclonal Anti-DXD&Exatecan Antibody, Mouse IgG1 is recombinantly produced from human 293 cells (HEK293).

### Isotype

Mouse IgG1/kappa

## Specificity

Specifically recognizes the target-DXD.

## Application

PK, PD, Immunoassay and ELISA

# Purity

>90% as determined by SDS-PAGE.

>90% as determined by SEC-MALS.

### Endotoxin

Less than 1.0 EU per  $\mu g$  by the LAL method.

# Formulation

Lyophilized from 0.22  $\mu m$  filtered solution in PBS, pH7.4 with trehalose as protectant.

Contact us for customized product form or formulation.

### Reconstitution

Please see Certificate of Analysis for specific instructions.

For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

### Storage


For long term storage, the product should be stored at lyophilized state at -20°C or lower.

Please avoid repeated freeze-thaw cycles.

This product is stable after storage at:


- -20°C to -70°C for 12 months in lyophilized state;
- $-70^{\circ}$ C for 3 months under sterile conditions after reconstitution.

## **SDS-PAGE**



Monoclonal Anti-DXD&Exatecan Antibody, Mouse IgG1 on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 90% (With <u>Star Ribbon Pre-stained Protein</u> <u>Marker</u>).

## SEC-MALS



The purity of Monoclonal Anti-DXD&Exatecan Antibody, Mouse IgG1 (Cat. No. DXD-M684) is more than 90% and the molecular weight of this protein is around 135-160 kDa verified by SEC-MALS. <u>Report</u>


## **Bioactivity-Elisa**




>>> www.acrobiosystems.com



Catalog # DXD-M684



Immobilized Trastuzumab-Exatcan at 1  $\mu$ g/mL (100  $\mu$ L/well) can bind Mouse Anti-DXD&Exatecan Antibody, Mouse IgG1, mAb (Cat. No. DXD-M684)



Immobilized ADC-DXD at 1 µg/mL (100 µL/well) can bind Mouse Anti-DXD&Exatecan Antibody, Mouse IgG1, mAb (Cat. No. DXD-M684) with a linear range of 0.1-4 ng/mL (Routinely tested).

#### Background

Dxd (Exatecan ADC derivative) is a potent DNA topoisomerase I inhibitor with an IC50 of 0.31 uM for targeting ADCs (DS-8201A). Dxd was cytotoxic to human tumor cell lines KPL-4, NCI-N87 and SK-BR, 3 and the IC50s of MDA-MB-468 was 1.43 NM-4.07 nM, while lgGADC (Dxd as payload) had no inhibitory effect on HER2 expression in the 4 cell lines. DS8201a (Dxd as payload) had a significant inhibitory effect on HER2-positive KPL-4 and NCI cell lines N87 and SK-BR with IC50 values of 26.8, 25.4 and 6.7 ng/mL, respectively, but had no inhibitory effect on MDA MB-468 (IC50, > 10000 - mL). HRP-anti-DXD-antibody is a conjugation product of HRP and anti-DXD-antibody. It can be used in PK, PD analysis and ELISA.

### **Clinical and Translational Updates**

with a linear range of 0.1-4 ng/mL (QC tested).





>>> www.acrobiosystems.com

